ICD-10-CM code Z83.42 identifies a patient's family history of familial hypercholesterolemia (FH), a life-threatening genetic condition that causes extremely high levels of low-density lipoprotein (LDL) cholesterol from birth. FH is most commonly inherited in an autosomal dominant pattern, meaning a child has a 50% chance of inheriting the disorder if one parent is affected. Because individuals with FH have a significantly elevated risk of premature atherosclerotic cardiovascular disease, including early-onset myocardial infarction and stroke, identifying a positive family history is a critical component of cardiovascular risk assessment. This code is used to trigger early screening (cascade testing), which is vital because early intervention with intensive lipid-lowering therapies, such as high-potency statins, ezetimibe, or PCSK9 inhibitors, can normalize life expectancy and substantially reduce the cumulative burden of cholesterol on the arterial walls. Clinical guidelines often recommend screening first-degree relatives of any individual diagnosed with FH or those with a family history of premature heart disease (men <55 years, women <65 years).
Distinguish specifically between a general family history of hyperlipidemia and the genetic diagnosis of familial hypercholesterolemia. Documentation must specify that the relative has the clinical or genetic diagnosis of FH, not just high cholesterol, to justify Z83.42.
Example: Patient is a 34-year-old male presenting for initial cardiovascular risk screening. Documentation reflects a confirmed diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH) in his biological father, who experienced a myocardial infarction at age 38. This specific family history supports more frequent lipid panels (CPT 80061) and potentially earlier initiation of statin therapy compared to general lipid screening guidelines.
Billing Focus: Identify the specific relationship of the affected family member (first-degree relative) and the exact clinical diagnosis of familial hypercholesterolemia to support higher complexity screening.
Document the specific phenotypic markers in family members that suggest familial hypercholesterolemia if a formal genetic diagnosis is unknown. Mentioning early-onset CAD, tendon xanthomas, or corneal arcus in relatives provides clinical evidence for the code.
Example: Patient has a significant family history of premature atherosclerotic cardiovascular disease. Her mother was diagnosed with familial hypercholesterolemia after presenting with bilateral Achilles tendon xanthomas and an LDL-C level exceeding 250 mg/dL. The documentation of these clinical markers in the relative justifies the use of Z83.42 for the patient's risk stratification.
Billing Focus: Clinical evidence in the relative (e.g., xanthomas) supports the medical necessity for 99213 or 99214 level of care when discussing preventive management strategies.
Incorporate the Simon Broome or Dutch Lipid Clinic Network criteria when documenting the family history. Explicitly stating that a relative meets these criteria strengthens the clinical validity of using Z83.42.
Example: Review of family history indicates a maternal aunt with a Dutch Lipid Clinic Network Score of 9, definitive for familial hypercholesterolemia. Patient is categorized as high-risk based on this genetic lineage, requiring a baseline carotid intima-media thickness study (CPT 93880).
Billing Focus: The use of formal scoring systems for the relative’s condition provides objective evidence for billing advanced diagnostic procedures.
When documenting for pediatric patients, specify the age of the affected relative's diagnosis. FH is often identified in childhood, and early documentation is essential for pediatric screening protocols.
Example: A 9-year-old patient is seen for wellness. Family history is positive for familial hypercholesterolemia in the father, diagnosed at age 12. In accordance with AAP guidelines for high-risk families, a fasting lipid profile (CPT 80061) is ordered today. The FH diagnosis in the parent is the primary driver for early screening.
Billing Focus: Pediatric screening based on Z83.42 supports the medical necessity of lipid panels prior to the standard age-9-to-11 window.
Clearly link the family history to the current plan of care, such as the decision to perform genetic testing or refer to a lipid specialist. This connection demonstrates the clinical utility of the code.
Example: Due to a strong family history of familial hypercholesterolemia (Z83.42) in two first-degree relatives, the patient is referred to a cardiologist for a specialized evaluation. Genetic counseling and testing for LDLR and APOB mutations are recommended to confirm the patient's carrier status.
Billing Focus: The referral and the complexity of the genetic counseling (CPT 96040) are directly supported by the specificity of Z83.42.
Appropriate for an initial consultation where a patient presents to discuss a new family history of FH and requires basic screening orders.
Used for follow-up visits to review lipid panel results after a patient was flagged with a family history of FH.
The primary diagnostic test used to screen patients who have a family history of FH.
Necessary for genetic confirmation of FH in a patient with a known family history.
Used when the family history is combined with the patient's own elevated lipids, requiring complex management and therapy initiation.
Often ordered to look for early atherosclerotic changes in patients with a strong family history of FH.
More accurate than calculated LDL in patients with severe dyslipidemia suggested by family history.
Standard of care for patients with a family history of FH to discuss inheritance patterns and testing options.
Used for discussing lifestyle and dietary changes specifically aimed at reducing cardiovascular risk from FH.
Part of the comprehensive lipid evaluation for a patient with family history of FH.